Last reviewed · How we verify
fixed dose combination therapy
A fixed dose combination therapy combines two or more active pharmaceutical ingredients in a single formulation to enhance therapeutic efficacy through synergistic or complementary mechanisms.
At a glance
| Generic name | fixed dose combination therapy |
|---|---|
| Sponsor | University of Western Ontario, Canada |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Fixed dose combinations are designed to improve patient compliance, optimize dosing ratios, and potentially reduce pill burden by delivering multiple drugs in one tablet or capsule. The specific mechanism depends on the individual components and their therapeutic targets, which are not specified for this generic category.
Approved indications
Common side effects
Key clinical trials
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (PHASE2)
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies (PHASE1)
- Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma (PHASE1, PHASE2)
- Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fixed dose combination therapy CI brief — competitive landscape report
- fixed dose combination therapy updates RSS · CI watch RSS
- University of Western Ontario, Canada portfolio CI